Skip to main content
OpenTrials
Completed

NCT Number: NCT05420207

Implantable Long-Acting Pre-Exposure Prophylaxis For MSM

The long-term goal of this project is to better understand factors at the patient and physician level that can be addressed to impact uptake of long-acting, implantable PrEP (LA-PrEP) products in the future and identify the training needs of physicians. This project specifically focuses on men who have sex with men (MSM) seen in primary care settings in Texas. The main objective of this project is to examine perspectives of MSM and physicians in Texas regarding LA-PrEP, including attitudes and barriers to use and implementation by interviewing patients and physicians from the same clinical practices.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HIV Prevention

Age range

18 year–45 year

Sex eligibility

Male

Study type

Observational

Primary location

University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Loading trial locations.

About this study

The long-term goal of this project is to better understand factors at the patient and physician level that can be addressed to impact uptake of long-acting, implantable PrEP (LA-PrEP) products and identify the training needs of physicians. This project is based on the hypothesis that specific barriers to uptake of LA-PrEP may exist that must be addressed to support widespread implementation in primary care settings in the future. Primary care settings are the ideal setting for new PrEP medications that employ innovative strategies for use, including implantable formulations, particularly among men who have sex with men (MSM). Primary care settings have demonstrated acceptability for other implantable medications, and similar strategies may be helpful for uptake of PrEP. However, new training and strategies will be needed for physicians to use this type of product with their patients should it become available. At this time, little is known about physician willingness to do the procedures required to insert the implant and what training will be needed. In particular, it is important to assess what training may be needed to effectively engage in health conversations with MSM patients. Thus, the main objective of this project is as follows: To examine perspectives of MSM (n=50) and physicians (n=20) in Texas regarding LA-PrEP, including attitudes and barriers to use and implementation by interviewing patients and physicians from the same clinical practices.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients must meet the following criteria:
  • be a patient of one of the practices where physicians have agreed to participate or have been seen for a primary care visit in the past 12 months in the Dallas Austin, or San Antonio metro areas;
  • be aged 18-45;
  • be assigned male sex at birth and report having one or more male sexual partners in the past year; and
  • be HIV negative.
  • Physicians who are interested in participating must be a practicing primary care physician in the Dallas, San Antonio, or Austin metropolitan area and be willing to allow recruitment of patient participants from their practice.

Exclusion criteria

  • Those individuals who speak a language other than English or Spanish will be excluded as well as those who present with a cognitive or other impairment that would prevent them for consenting to participate in the study.

Treatment and study plan

No intervention

Other

No intervention included

Primary outcomes

  1. Patient readiness to use LA-PrEP assessed via patient interview

    Time frame: Baseline

    Patient readiness to use Long-Acting, implantable Pre-exposure prophylaxis (LA-PrEP) is assessed via interview asking men who have sex with men (MSM) patients to respond to the following question: There may be opportunities in the future to have access to products that prevent HIV that are long-acting (LA) and are implanted under the skin. What are your thoughts on using this type of product if it becomes available for use? This is a qualitative measure and will report the summary of responses.

  2. Patient readiness to use LA-PrEP as measured by a 10-item investigator developed questionnaire

    Time frame: Baseline

    Patient readiness to use LA-PrEP is measured by a 10-item investigator developed questionnaire where participants will be asked to rate the importance of 10 items regarding their readiness to use implantable long-acting PrEP on a scale of 1-10. Each item will be rated on a scale of 1-10. The mean for each item will be reported. Higher score is higher readiness.

  3. Facilitators to LA-PrEP uptake and adherence assessed via patient interview

    Time frame: Baseline

    Facilitators to LA-PrEP uptake and adherence is assessed by asking questions to MSM patients via an interview which will include 3 questions on the following:

    • Likeliness of using a long-acting HIV prevention subdermal implant that is implanted under the skin if it were available.
    • Recommended strategies to help increase uptake of LA-PrEP among MSM patients in primary care.
    • Perceptions on what physicians can do to increase uptake of LA-PrEP should it become available.

    This is a qualitative measure and will report the summary of responses.

  4. PrEP Stigma in both cohorts (MSM patients and primary care physicians)

    Time frame: Baseline

    PrEP Stigma in both cohorts (MSM patients and MSM physicians) is measured by the PrEP stigma and positive attitude scale. The PrEP stigma scale is assessed by 7 questions in both cohorts (MSM patients and physicians). Possible scores range from 1-5 where higher score indicates higher levels of stigma. Scores will be calculated by using the mean score of all items for the factor.

  5. Positive Attitudes towards PrEP in both cohorts (MSM patients and primary care physicians)

    Time frame: Baseline

    Positive Attitudes towards PrEP in both cohorts (MSM patients and MSM physicians) is measured by the PrEP stigma and positive attitude scale. The Positive Attitudes towards PrEP scale is assessed by 3 questions in both cohorts (MSM patients and physicians). Possible scores range from 1-5 where higher scores indicate more positive attitudes. Scores will be calculated by using the mean score of all items for the factor.

  6. Physician comfort with PrEP Clinical Activities as measured by an adapted scale (Petroll and colleagues)

    Time frame: Baseline

    Physician comfort with PrEP Clinical Activities is measured by an adapted scale (Petroll and colleagues) that includes rating their comfort level regarding 11 clinical activities using a scale of 1-5 where 1 is "completely uncomfortable" and 5 is "completely comfortable." We will sum the total score.

  7. Facilitators to LA-PrEP uptake and adherence assessed via physicians' interview

    Time frame: Baseline

    Facilitators to LA-PrEP uptake and adherence is assessed by asking questions to physicians via an interview which will include 2 questions on the following:

    • What would make it easier or more likely you would use an implantable form of PrEP with patients who are gay or bisexual men ?
    • What would make it easier to implement use of a LA subdermal HIV prevention implant in your practice and why?

    This is a qualitative measure and will report the summary of responses.

  8. Physician Training Needs as assessed via physician interview

    Time frame: Baseline

    Physician Training Needs are assessed via physician interview that will include 2 questions asking the type of training required to prepare physicians -

    • to discuss LA-PrEP with patients, and,
    • to insert an LA-PrEP implant and remove it

    This is a qualitative measure and will report the summary of responses.

  9. Physician Training Needs rating as measured by investigator developed scale

    Time frame: Baseline

    Physician Training Needs rating is measured by an investigator developed scale of 1-10 where participants will be asked to rate how helpful would it be to include 10 specific types of content in a training on long acting implantable PrEP. The mean rating for each item will be reported. Possible scores range from 1-10 where higher scores indicate higher levels of perceived helpfulness.

Sponsors and collaborators

Lead sponsor

Elizabeth Arnold

Other

Collaborators

  • Merck Sharp & Dohme LLC

Registry information

Official study title

Implantable Long-Acting Pre-Exposure Prophylaxis for HIV Prevention With MSM: A Qualitative Study of Patient and Physician Perspectives

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jun 15, 2022
Registry last updated
Oct 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.